BG63917B1 - 1-ar(alk)yl-imidazolin-2-ones with disubstituted amine residue in the 4th place, with anti-convulsive effect and method for their preparation - Google Patents
1-ar(alk)yl-imidazolin-2-ones with disubstituted amine residue in the 4th place, with anti-convulsive effect and method for their preparation Download PDFInfo
- Publication number
- BG63917B1 BG63917B1 BG102287A BG10228798A BG63917B1 BG 63917 B1 BG63917 B1 BG 63917B1 BG 102287 A BG102287 A BG 102287A BG 10228798 A BG10228798 A BG 10228798A BG 63917 B1 BG63917 B1 BG 63917B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- imidazolin
- morpholino
- chlorophenyl
- preparation
- alk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Област на техникатаTechnical field
Изобретението се отнася до 1-ар(алк)ил- 10 имидазолин-2-они, които съдържат на четвърто място дизаместен аминов остатък, метод за тяхното получаване и използването им като фармацевтични средства за лечение на заболявания на централната нервна система, по- 15 специално на различни форми на епилепсия.The invention relates to 1-ar (alk) yl-10-imidazolin-2-ones, which contain a fourth disubstituted amine residue, a method for their preparation and their use as pharmaceuticals for the treatment of diseases of the central nervous system, especially of various forms of epilepsy.
Предшестващо състояние на техникатаBACKGROUND OF THE INVENTION
1-ар(алк)ил-имидазалин-2-онис незамес- 20 тен аминов остатък или метиламинов остатък на 4-място се получават съгласно предшестващото ниво на техниката чрез взаимодействие на ар (алк) иламиноацетамиди с бромоциан. Чрез N-алкилиране на така получените 4-амино-1- 25 ар(алк)ил-имидазолин-2-они се получават 3-алкилили 1-иминоалкил-3-алкил-1-ар(алк) ил-имвдазолин-2-они, при което аминогрупата в 4 място се превръща в тавтомерната иминогрупа. Понататъшно N-алкилиране до съединения с об- 30 ща формула I поради това не е възможно, така че съединенията съгласно изобретението не могат да се получат по този метод [USP 4044021; DE 225 1354].1-ar (alk) yl-imidazalin-2-oneis unsubstituted amine moiety or methylamine moiety in 4-position was prepared according to the prior art by reacting a? (Alk) ylaminoacetamides with bromocyanine. N-alkylation of the 4-amino-1- 25 ar (alk) yl-imidazolin-2-one thus obtained yields 3-alkylily 1-iminoalkyl-3-alkyl-1-ar (alk) yl-imvdazolin-2- they, in which the amino group in the 4th place becomes the tautomeric amino group. Further N-alkylation to compounds of general formula I is therefore not possible, so that the compounds of the invention cannot be prepared by this method [USP 4044021; DE 225 1354].
1-ар(алк)ил-имидазолин-2-онисдизамес- 35 тен аминов остатък на четвъртото място досега не са описани.The 1-ar (alk) yl-imidazolin-2-one disubstituted amine residue in the fourth position has not been described so far.
Известни са много съединения с антиконвулсивно действие. До днес обаче не могат да се лекуват задоволително всички епилеп- 40 тични заболявания.Many compounds with anticonvulsant activity are known. However, to date, not all epileptic diseases can be treated satisfactorily.
Задача на настоящото изобретение е да се създадат нови съединения със задоволителни фармакологични свойства, които могат да се използват като антиепилептично действащи 45 лекарствени средства.It is an object of the present invention to provide novel compounds with satisfactory pharmacological properties that can be used as anti-epileptically acting 45 drugs.
Техническа същност на изобретениетоSUMMARY OF THE INVENTION
Съгласно изобретението тези нови съе- 50 динения са 1-ар(алк)ил-имидазолин-2-они с обща формула IAccording to the invention, these new compounds are 1-ar (alk) yl-imidazolin-2-ones of general formula I
(I) в която:(I) in which:
X означава халоген, Смалкил или С14 алкоксигрупа;X represents halogen, C 1-4 alkyl or C 14 alkoxy;
η означава 0 или 1;η is 0 or 1;
ш означава 0 или 1;y is 0 or 1;
R означава морфолинов, пиперидинов, метилпиперазинов остатък, хексаметиленимино група, диметиламинова или циклохексилметиламинова група.R represents a morpholine, piperidine, methylpiperazine residue, hexamethyleneimino group, dimethylamine or cyclohexylmethylamine group.
Като примери на съединения с обща формула I могат да се посочат.Examples of compounds of general formula I may be cited.
-фенил-4-морфолино-имидазолин-2-он;-phenyl-4-morpholino-imidazolin-2-one;
- (4-метоксифенил) -4-пиперидино-имидазолин-2-он;- (4-methoxyphenyl) -4-piperidino-imidazolin-2-one;
- (4-хлорофенил) -4-морфолино-имидазолин-2-он;- (4-chlorophenyl) -4-morpholino-imidazolin-2-one;
- (4-хлорофенил) -4-пиперидино-имидазолин-2-он;- (4-chlorophenyl) -4-piperidino-imidazolin-2-one;
- (4-хлорофенил) -4-диметиламино-имидазолин-2-он;- (4-chlorophenyl) -4-dimethylamino-imidazolin-2-one;
- (4-бромофенил) -4-морфолино-имидазолин-2-он;- (4-bromophenyl) -4-morpholino-imidazolin-2-one;
- (3-хлорофенил) -4-морфолино-имидазолин-2-он;- (3-chlorophenyl) -4-morpholino-imidazolin-2-one;
- (4-хлорофенил) -4-хексаметиленаминоимидазолин-2-он;- (4-chlorophenyl) -4-hexamethyleneaminoimidazolin-2-one;
- (4-хлорофенил) -4- (4-метилпиперазино) -имидазолин-2-он;- (4-chlorophenyl) -4- (4-methylpiperazino) -imidazolin-2-one;
- (4-метилфенил) -4-морфолино-имидазолин-2-он;- (4-methylphenyl) -4-morpholino-imidazolin-2-one;
- (4-хлорофенил) -4- (циклохексил-метиламино) -имидазолин-2-он;- (4-chlorophenyl) -4- (cyclohexyl-methylamino) -imidazolin-2-one;
- (4-флуорофенил) -4-морлфолино-имидазолин-2-он;- (4-fluorophenyl) -4-morpholino-imidazolin-2-one;
-бензил-4-морфолино-имидазолин-2-он. Съгласно изобретението съединенията с обща формула I се получават от съединения с обща формула II-benzyl-4-morpholino-imidazolin-2-one. According to the invention, the compounds of general formula I are prepared from compounds of general formula II
в която:wherein:
X означава халоген, Смалкил или См алкокси група;X stands for halogen, C 1-4 alkyl or C 1-4 alkoxy;
η означава 0 или 1;η is 0 or 1;
m означава 0 или 1;m is 0 or 1;
с вторичен амин RH, при което R има посочените по-горе значения.with a secondary amine RH, wherein R has the meanings indicated above.
Получаването на съединенията с обща формула I може да се осъществи по избор в 5 разтворител или в излишък от вторичния амин, при температури между 50°С и 160°С. Като разтворители се имат предвид за предпочитане ароматни въглеводороди например бензен, толуен, хлоробензен или дихлоробензен.The preparation of the compounds of general formula I can be carried out optionally in 5 solvent or in excess of the secondary amine at temperatures between 50 ° C and 160 ° C. Preferably, solvents are aromatic hydrocarbons, for example benzene, toluene, chlorobenzene or dichlorobenzene.
За предпочитане се работи в присъствие на свързващи водата средства като зеолити или натриев сулфат. Реакцията може да бъде ускорена чрез прибавяне на обичайни за кондензация катализатори като 4-толуенсулфонова киселина.Preferably, it is present in the presence of water binders such as zeolites or sodium sulfate. The reaction can be accelerated by the addition of conventional condensation catalysts such as 4-toluenesulfonic acid.
Съединенията съгласно настоящото изобретение са подходящи за приготвяне на фармацевтични състави.The compounds of the present invention are suitable for the preparation of pharmaceutical compositions.
Фармацевтичните състави могат да съдържат едно или повече от съединенията съгласно изобретението. За приготвянето или фармацевтичните препарати могат да се използват обичайни фармацевтични носители и помощни вещества.The pharmaceutical compositions may contain one or more of the compounds of the invention. Conventional pharmaceutical carriers and excipients may be used for the preparation or pharmaceutical preparations.
Лекарствените средства могат да се прилагат парентерално (например венозно, мускулно, подкожно) или орално.The drugs may be administered parenterally (eg, intravenously, intramuscularly, subcutaneously) or orally.
Формите за приложение могат да се приготвят съгласно общоизвестни и обичайни във фармацевтичната практика методи.Formulations for administration may be prepared according to conventional and conventional pharmaceutical methods.
Съединенията съгласно изобретението показват силно антиконвулсивно действие.The compounds of the invention exhibit a strong anticonvulsant activity.
Те се изпитват за антиконвулсивно дей10 ствие in vivo, след i.p. приложение на мишки или на плъхове (р.о. прилагане), по обичайни международни стандарти (Pharm. Weekblad, Sc.Ed. 14,132 (1992) и Antiepileptic Drugs, Third Ed., Raven Press, New York 1989) Таблица 1.They are tested for anticonvulsant activity in vivo after i.p. administration of mice or rats (p.o. administration), by conventional international standards (Pharm. Weekblad, Sc.Ed. 14,132 (1992) and Antiepileptic Drugs, Third Ed., Raven Press, New York 1989) Table 1.
Например, за съединението 2 (1-(4-хлорофенил)-4-морфолино-имидазолин-2-он) се определя при плъхове, за максимален електрошок, EDM (р.о.) 21 mg/kg, при s.c. пентетразолов тест EDJ0 е 16 mg/kg и за невротоксич20 ност NTJ0 е > 400 mg/kg. В сравнение с това, познатите антиепилептици, които действат или при модела на максимален електрошок, или при пентетразолов тест, или при по-силно действие в пентетразолов тест, са силно невротоксични.For example, for compound 2 (1- (4-chlorophenyl) -4-morpholino-imidazolin-2-one) was determined in rats, for maximum electroshock, ED M (p.o.) 21 mg / kg, for the pentetrazole test ED J0 is 16 mg / kg and for neurotoxicity NT J0 is> 400 mg / kg. In comparison, known anti-epileptics, which act in either the maximal electroshock model, or the pentetrazole test, or more potently in the pentetrazole test, are highly neurotoxic.
Таблица 1.Table 1.
Забележка към таблица 1:Note to Table 1:
1) Номериране на съединенията в примерите за изпълнение1) Numbering of the compounds in the embodiments
2) Коефициент на разпределение етанол/ вода2) Ethanol / water partition coefficient
3) Мишки i.p.: MES = максимален електрошок,3) Mice i.p .: MES = maximum electroshock,
PTZ = s.c. пентетразолPTZ = s.c. pentetrazole
4) в mg/kg4) in mg / kg
5) в % от защитените животни5) in% of protected animals
Примери за изпълнение на изобретениетоExamples of carrying out the invention
Получаването на новите съединения с обща формула I се изяснява по-добре въз основа на примерите за изпълнение.The preparation of the new compounds of general formula I is better elucidated based on embodiments.
Обща методика за получаването на съединенията с формула I съгласно таблица 1, примери 1-11.General procedure for the preparation of the compounds of formula I according to Table 1, Examples 1-11.
Вариант АOption A
0,05 mol 1-арил-имидазолин-2,4-дион с обща формула II (п=О) и 200 mg 4-толуенсулфонова киселина се прибавят към 100 ml съответен вторичен амин. След това се нагрява под обратен хладник в Сокслет-екстрактор, при което екстракционната гилза е напълнена предварително с около 25 g свързващо водата твърдо вещество (подходящи са калц. натриев сулфат, магнезиев сулфат, NaOH, КОН, зеолит). След 8 до 30 h реакционно време разтворът се филтрира на горещо и на ротационен изпарител се дестилира до около половината от обе10 ма. Бистрият разтвор се охлажда на ледена баня и изпадащата кристална каша се отделя от амина. Полученото като суров продукт изходно вещество се екстрахира с 50 ml горещ ацетон. Продуктът се прекристализира из нормпропанол.0.05 mol of 1-aryl-imidazoline-2,4-dione of general formula II (n = O) and 200 mg of 4-toluenesulfonic acid are added to 100 ml of the corresponding secondary amine. It is then refluxed in a Soxhlet extractor, whereby the extraction sleeve is pre-filled with about 25 g of a water binder (calcium sulphate, magnesium sulfate, NaOH, KOH, zeolite). After 8 to 30 hours of reaction time, the solution was filtered hot and the rotary evaporator distilled to about half of both 10 mA. The clear solution was cooled in an ice bath and the resulting crystalline slurry was separated from the amine. The starting material obtained as a crude product was extracted with 50 ml of hot acetone. The product was recrystallized from normpropanol.
От отделения амин може да се получи обратно около 0,02 mol непрореагирал 1-арилимидазолин-2,4-дион.About 0.02 mol of unreacted 1-arylimidazoline-2,4-dione can be recovered from the separated amine.
Вариант В.Option B.
0.05 mol 1-аралкил-имидазолин-2,4-дион с обща формула (II) (η-l) взаимодейства с вторичен амин, както е описано в А. След 8 до 30 h реакционно време разтворът се филтрира на горещо и след това се изпарява до сухо на ротационен изпарител. Към остатъка се прибавят 50 ml метиленхлорид и 50 ml 2N НС1. Органичната фаза се отделя и водната фаза се екстрахира още два пъти с метиленхлорид. Отделената водна фаза се алкализира с 50 ml 10%-ен NaOH и 1-(4-амино)-1-аралил-имидазолин-2-он се екстрахира със 100 ml метиленхлорид. Етерните екстрати се сушат с натриев сулфат. След дестилиране на метиленхлорида суровият продукт се прекристализира из етанол и ацетон.0.05 mol of 1-aralkyl-imidazoline-2,4-dione of general formula (II) (η-1) is reacted with a secondary amine as described in A. After 8 to 30 hours the reaction time is filtered hot and then evaporated to dryness on a rotary evaporator. 50 ml of methylene chloride and 50 ml of 2N HCl were added to the residue. The organic phase was separated and the aqueous phase extracted twice more with methylene chloride. The separated aqueous phase was basified with 50 ml of 10% NaOH and 1- (4-amino) -1-aryl-imidazolin-2-one was extracted with 100 ml of methylene chloride. The ether extracts were dried with sodium sulfate. After distillation of the methylene chloride, the crude product was recrystallized from ethanol and acetone.
Вариант С.Option C.
0,05 mol 1-ар-(алк)ил-имидазолин-2,4-дион с обща формула взаимодейства със 100 ml диметиламониев диметилкарбамат, както е описано в А и В. След 40 h реакционно време се довършва по вариант А или В.0.05 mol of 1-ar- (alk) yl-imidazoline-2,4-dione of the general formula is reacted with 100 ml of dimethylammonium dimethylcarbamate as described in A and B. After 40 hours, the reaction time is completed in option A or B .
Таблица 2.Table 2.
i) регенерираното изходно вещество се взема предвид при изчисляването на добивите 40(i) the recovered starting material is taken into account in the calculation of the yields 40
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19532668A DE19532668A1 (en) | 1995-09-05 | 1995-09-05 | Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation |
PCT/EP1996/003295 WO1997009314A1 (en) | 1995-09-05 | 1996-07-26 | Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anti-convulsive effect, and process for their production |
Publications (2)
Publication Number | Publication Date |
---|---|
BG102287A BG102287A (en) | 1998-09-30 |
BG63917B1 true BG63917B1 (en) | 2003-06-30 |
Family
ID=7771261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102287A BG63917B1 (en) | 1995-09-05 | 1998-02-27 | 1-ar(alk)yl-imidazolin-2-ones with disubstituted amine residue in the 4th place, with anti-convulsive effect and method for their preparation |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0863880B1 (en) |
JP (1) | JP4030578B2 (en) |
CN (1) | CN1103762C (en) |
AR (1) | AR003502A1 (en) |
AT (1) | ATE254606T1 (en) |
AU (1) | AU700602B2 (en) |
BG (1) | BG63917B1 (en) |
BR (1) | BR9610359A (en) |
CA (1) | CA2184871C (en) |
CZ (1) | CZ291839B6 (en) |
DE (2) | DE19532668A1 (en) |
DK (1) | DK0863880T3 (en) |
EA (1) | EA000535B1 (en) |
EE (1) | EE03562B1 (en) |
ES (1) | ES2208758T3 (en) |
FR (1) | FR13C0049I2 (en) |
GE (1) | GEP20022652B (en) |
HK (1) | HK1015776A1 (en) |
HU (1) | HU225956B1 (en) |
IL (1) | IL123333A (en) |
LT (1) | LT4482B (en) |
LU (1) | LU92263I2 (en) |
NO (1) | NO313829B1 (en) |
NZ (1) | NZ315624A (en) |
PL (1) | PL188287B1 (en) |
PT (1) | PT863880E (en) |
SK (1) | SK284868B6 (en) |
TR (1) | TR199800476T1 (en) |
TW (1) | TW422838B (en) |
UA (1) | UA46790C2 (en) |
WO (1) | WO1997009314A1 (en) |
ZA (1) | ZA967014B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19721580A1 (en) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension |
US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
MXPA05013196A (en) * | 2003-07-11 | 2006-03-09 | Elbion Ag | Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor. |
EP2093218A1 (en) * | 2008-02-22 | 2009-08-26 | Ruggero Fariello | Arylalkyl substituted imidazolidinones |
JP2014521714A (en) | 2011-08-12 | 2014-08-28 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Odd isomer current (If) inhibitors for use in methods of treating and preventing feline heart failure |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
IT202100000782A1 (en) | 2021-01-18 | 2022-07-18 | Procos Spa | PROCESS FOR THE SYNTHESIS OF IMEPITOIN |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE790380A (en) | 1971-10-21 | 1973-04-20 | American Cyanamid Co | NEW (P-CHLORO) PHENYL-1 METHYL-3 IMIDAZOLIDINES, 2,4-DISUBSTITUTIONS USEFUL IN PARTICULAR AS ANTIALDOSTERONE DIURETIC AGENTS AND THEIR PREPARATION PROCESS |
US4044021A (en) * | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
US3932452A (en) * | 1975-02-07 | 1976-01-13 | Morton-Norwich Products, Inc. | 1-Arylmethyl-2-imidazolidinones |
-
1995
- 1995-09-05 DE DE19532668A patent/DE19532668A1/en not_active Ceased
-
1996
- 1996-07-26 AU AU67375/96A patent/AU700602B2/en not_active Expired
- 1996-07-26 DE DE59610827T patent/DE59610827D1/en not_active Expired - Lifetime
- 1996-07-26 UA UA98041717A patent/UA46790C2/en unknown
- 1996-07-26 PL PL96325413A patent/PL188287B1/en unknown
- 1996-07-26 CN CN96197801A patent/CN1103762C/en not_active Expired - Lifetime
- 1996-07-26 ES ES96927607T patent/ES2208758T3/en not_active Expired - Lifetime
- 1996-07-26 GE GEAP19964221A patent/GEP20022652B/en unknown
- 1996-07-26 AT AT96927607T patent/ATE254606T1/en active
- 1996-07-26 SK SK216-98A patent/SK284868B6/en not_active IP Right Cessation
- 1996-07-26 EA EA199800271A patent/EA000535B1/en not_active IP Right Cessation
- 1996-07-26 HU HU9802941A patent/HU225956B1/en unknown
- 1996-07-26 DK DK96927607T patent/DK0863880T3/en active
- 1996-07-26 WO PCT/EP1996/003295 patent/WO1997009314A1/en active IP Right Grant
- 1996-07-26 IL IL12333396A patent/IL123333A/en not_active IP Right Cessation
- 1996-07-26 EP EP96927607A patent/EP0863880B1/en not_active Expired - Lifetime
- 1996-07-26 EE EE9800063A patent/EE03562B1/en unknown
- 1996-07-26 TR TR1998/00476T patent/TR199800476T1/en unknown
- 1996-07-26 NZ NZ315624A patent/NZ315624A/en not_active IP Right Cessation
- 1996-07-26 BR BR9610359A patent/BR9610359A/en active IP Right Grant
- 1996-07-26 PT PT96927607T patent/PT863880E/en unknown
- 1996-07-26 JP JP51080097A patent/JP4030578B2/en not_active Expired - Lifetime
- 1996-07-26 CZ CZ1998661A patent/CZ291839B6/en not_active IP Right Cessation
- 1996-08-19 ZA ZA967014A patent/ZA967014B/en unknown
- 1996-09-03 TW TW085110749A patent/TW422838B/en not_active IP Right Cessation
- 1996-09-04 AR ARP960104226A patent/AR003502A1/en active IP Right Grant
- 1996-09-05 CA CA002184871A patent/CA2184871C/en not_active Expired - Lifetime
-
1998
- 1998-02-27 BG BG102287A patent/BG63917B1/en unknown
- 1998-03-02 NO NO19980906A patent/NO313829B1/en not_active IP Right Cessation
- 1998-04-03 LT LT98-047A patent/LT4482B/en not_active IP Right Cessation
-
1999
- 1999-03-01 HK HK99100827A patent/HK1015776A1/en not_active IP Right Cessation
-
2013
- 2013-08-07 LU LU92263C patent/LU92263I2/en unknown
- 2013-08-13 FR FR13C0049C patent/FR13C0049I2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2637737B2 (en) | New drugs | |
EP0054951A1 (en) | Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same | |
EP0025111A1 (en) | 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them | |
EP0000220B1 (en) | Dihydrouracils, process for their preparation and pharmaceuticals containing them | |
US3558652A (en) | N-monosubstituted pyrrylaminoethanols | |
BG63917B1 (en) | 1-ar(alk)yl-imidazolin-2-ones with disubstituted amine residue in the 4th place, with anti-convulsive effect and method for their preparation | |
DE2851028A1 (en) | NEW INDOLO SQUARE CLAMP ON 2.3-A SQUARE CLAMP ON CHINOLICIDINE, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATION CONTAINING IT | |
DE2424671C3 (en) | 5,6-dihydro-s-triazolo [5,1-a] isoquinoline derivative and process for their preparation | |
FI60863C (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA BENTSHYDRYLOXIALKYLAMINDERIVAT MED FOERLAENGD ANTIHISTAMINEFFEKT | |
US3213140A (en) | 2-phenyl-4, 6-dichlorophenoxyethylamine and salts thereof | |
CH627175A5 (en) | ||
US4259257A (en) | 1-Phenyl-2-amino-1,3-propanediol-N-aryloxyalkyl derivatives | |
EP0338435A1 (en) | 3,4-Dihydroxypyrrolidin-2-one derivatives, process for their preparation, agents containing them and their use as well as the intermediates resulting from the preparation | |
US4161532A (en) | N-(1'-ethyl-2'-oxo-5'-pyrrolidinylmethyl) benzamide compounds and derivatives, method of preparation and pharmaceutical preparations | |
US4113877A (en) | Substituted 2-aminomethylphenyl sulfamates | |
DE1643265C3 (en) | Nuclear-substituted 2-aminomethylbenzhydrols, processes for their preparation and pharmaceuticals based on these compounds | |
US3074953A (en) | 5-(3'-(4-phenyl-4-carbethoxy piperidino)-propylidene) dibenzo (a,d) (1,4) cycloheptadiene | |
FI64591B (en) | FRUIT PROCESSING FOR THERAPEUTIC THERAPY 4- (2-BENZOFURYL) -1-PYRROLINDERIVAT | |
HU191585B (en) | Process for producing tetramethyl-proline-3-carboxamide derivatives and new cardiotherapeutic compositions containing them | |
FR2567517A1 (en) | AMMONIUM SALTS DERIVED FROM HEXAHYDRODIBENZODIOXANE, THEIR INTERMEDIATES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
MXPA98001742A (en) | New 1-ar (alqu) il-imidazolin-2-onas, which are conposition 4, contains a rested amino resort, of anticonvulsive effect and procedures for suelaborac | |
HU181441B (en) | Process for producing substituted quinolizidine and indolizidine derivatives | |
CS216172B2 (en) | Method of making the n-substituted n-2-+l2-furylethyl+p-amines | |
DE2337414A1 (en) | 2-IMIDAZOLIDINONE DERIVATIVES AND PROCESS FOR THE PREPARATION | |
EP0175331A1 (en) | Piperazine Derivatives |